Introduction by Professor Keyvan Moghissi

This Centre is working at the forefront of the use of lasers in the treatment of cancer and other life threatening conditions. It works in partnership with the NHS and is supported by Moghissi Laser Trust (Charity No. 326689), which was established in 1984. The team has pioneered the development of photodynamic therapy (PDT) which combines the use of lasers with a photo-sensitive drug to provide highly targeted treatment.

Work continues to develop the effectiveness of PDT in different parts of the body and in the exciting new area of photo-detection (PD) which can identify abnormalities under laser light long before traditional techniques. Ongoing research, treatment and training is making a significant contribution to advances in effective laser therapies in the UK and overseas.

I have been supported by an excellent team of colleagues and associates who have helped us to achieve an international reputation funded primarily thr ough charitable donation.

This web site has been created to give the public and professionals a concise introduction to the Centre. In addition to general information About Us and background information on Our Work there is Medical information for health professionals, News and resources for the media and links to make Donations on-line. If there is anything you cannot find on the site please do not hesitate to Contact Us for more information.

By viewing this web site you agree to abide by our Terms and Conditions of access.

Thank you for your interest and support.


Prof Keyvan Moghissi
BSc., M.D.,F.R.C.S.(Ed.), F.R.C.S.(Eng.), F.E.T.C.S.
Membre Associe Academie de Chirugie Paris
Clinical Director



Our work at the Yorkshire Laser Centre includes clinical trials of the effects of Photodynamic Therapy on different types of cancer. Some of the trials we have recently conducted include;


PDT Clinical studies


Title of study


No’s of patients recruited.


Lung Cancer


Study of the role of PDT in early central lung cancer: pilot study (K Moghissi YLC)





(for early lung cancer)


A pilot study of the accuracy of fluorescence bronchoscopy versus white light bronchoscopy in the detection of early bronchogenic cancer in high-risk individuals (K Moghissi YLC)




Oesophageal Cancer


Non-randomised comparison between endoscopic PDT and surgical resection in patients with early (stage I) oesophageal cancer (K Moghissi YLC)


80 (40 for each arm)


Oesophageal Cancer


Study to determine the place of endoscopic PDT within the range of treatment for oesophageal cancer. Matched pair subjects (K Moghissi YLC)


280 out of 1343 patients





Study of the role of PDT in VIN: single or multiple PDT cycle (non-randomised prospective) – (C Gan Consultant Gynaecologist NLAG NHS Trust/YLC)


30 patients to date




Pilot study of the role of PDT in AIN in patients with or without HIV (G Duthie Dept of Academic Surgery/YLC)






Pilot study of the role of PDT in urothelial cancer ( L Coombs Consultant Urological Surgeon NLAG NHS Trust/YLC)


6 patients to date

Here at the Yorkshire Laser Centre we care about our patients and are aware that the knowledge of which options will help with your condition is key to decision making process and allowing you moving on with your life.

To help those that have been diagnosed with cancer we are happy to complete a thorough electronic review of your case notes to confirm if Photodynamic Therapy would help with your condition. As this is a premium service we do need to charge for the time this takes and the charge for this is £120.

If this is of interest to you please contact us and we can arrange for you to email your notes to us and supply the details for you to pay via Paypal.

Concerns around so-called ‘next generation’ PDT and sonodynamic therapy

Photodynamic therapy (PDT) is a treatment option for some types of cancer that involves administration of a drug that is activated by light, usually from a laser. This causes cell death. The underlying scientific principles and numerous clinical studies have been published in peer-reviewed literature1 2 3.  PDT can be curative. For example, in non-melanoma skin cancers, PDT has less morbidity than cryotherapy and avoids the need for skin grafts in surgical excision of large lesions. Often it is palliative where it can bring welcome symptomatic relief and precious extra months’ quality life to the patient.

PDT has several key attractions: there is minimal loss of normal tissue; PDT can be repeated in the same area as often as required; it can be used after conventional treatments have failed or as a stand-alone treatment in appropriate patients.

There are clinics providing what is sometimes called Next Generation PDT (NGPDT) or sonodynamic therapy (SDT). In general, the treatments provided do not have the necessary scientific rigour that is expected. Often the light is delivered externally and it is claimed that this reaches the tumour but light penetration to internal cancers is insufficient for effective PDT. A critical appraisal of a clinical application of SDT has been published4. This concludes that there is no convincing data that shows that treatment carried out as reported is effective in the treatment of primary tumour and multiple metastases. Without critical safety and efficacy information, it is unjustifiable to test unproven unconventional techniques and substances in patients, particularly those in terminal stages.

PDT can be used effectively in the treatment and care of appropriate cancer patients

The use of so-called NGPDT or SDT cannot be recommended.


Prof Harry Moseley, Hon President British Medical Laser Association; Prof Sam Eljamel, Clinical Director Scottish PDT Centre; Prof Keyvan Moghissi, Clinical Director Yorkshire Laser Centre



1              Moghissi K, Dixon K, Stringer M et al. Photofrin PDT for early stage oesophageal cancer: Long term results in 40 patients and literature review. Photodiagnosis and Photodynamic Therapy 2009; 6: 159-66.

2              Allison RR, Sibata C, Gay H. PDT for cancers of the head and neck. Photodiagnosis and Photodynamic Therapy 2009; 6: 1-2.

3              Morton CA, McKenna KE, Rhodes LE et al. Guidelines for topical photodynamic therapy: update. British Journal of Dermatology 2008; 159: 1245-66.

4              Huang Z, Moseley H, Bown S. Rationale of Combined PDT and SDT Modalities for Treating Cancer Patients in Terminal Stage: The Proper Use of Photosensitizer. Integrative Cancer Therapies 2010; 9: 317-9.